Steve Bender
Impact in
-
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
- Oncology top 10%
- Cancer Cells and Metastasis
Papers in
- Oncology 7
- Cancer Cells and Metastasis 2
- HER2/EGFR in Cancer Research 2
-
- Angiogenesis and VEGF in Cancer 2
- PI3K/AKT/mTOR signaling in cancer 2
- Co-authors
- David R. Shalinsky (3 shared papers)Jeffrey H. Chen (1 shared paper)Grant Wickman (2 shared papers)Dana D. Hu‐Lowe (2 shared papers)Patrick M. O’Connor (1 shared paper)Michele McTigue (2 shared papers)David A. Rewolinski (1 shared paper)Xinglin Wu (1 shared paper)
- Journals
- Cancer Research (4 papers)Clinical Cancer Research (2 papers)Journal of Medicinal Chemistry (1 paper)Molecular Cancer Therapeutics (1 paper)PLoS ONE (1 paper)
- Partner nations
- United StatesUnited Kingdom
In The Last Decade
Steve Bender
10 papers receiving 672 citations
Steve Bender's Hit Papers
Peers
Comparison fields: 5 of 74
- Cancer Research 120
- Oncology 215
- Pulmonary and Respiratory Medicine 224
- Molecular Biology 330
- Pathology and Forensic Medicine 50
Countries citing papers authored by Steve Bender
This map shows the geographic impact of Steve Bender's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Bender with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Bender more than expected).
Fields of papers citing papers by Steve Bender
This network shows the impact of papers produced by Steve Bender. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Bender. The network helps show where Steve Bender may publish in the future.
Co-authors
The 25 scholars most cited alongside Steve Bender, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 Hit paper breakdown → | 2008 | 540 |
| 2 | 2010 | 61 | |
| 3 | 2013 | 36 | |
| 4 | 2006 | 20 | |
| 5 | 2008 | 8 | |
| 6 | 2014 | 8 | |
| 7 | AG-028262, a novel selective VEGFR tyrosine kinase antagonist that potently inhibits KDR signaling and angiogenesis in vitro and in vivo | 2004 | 7 |
| 8 | 2003 | 4 | |
| 9 | Receptor tyrosine kinase cross talk affects tumor cell sensitivity to RTK inhibitors | 2008 | 2 |
| 10 | 2010 | 1 |
About Steve Bender
Steve Bender is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Biotechnology and Cancer Research, having authored 10 papers that have together received 687 indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (2 papers), Cancer Genomics and Diagnostics (2 papers), Cancer Cells and Metastasis (2 papers), Lung Cancer Treatments and Mutations (2 papers), PI3K/AKT/mTOR signaling in cancer (2 papers), HER2/EGFR in Cancer Research (2 papers), Nerve injury and regeneration (1 paper) and Toxin Mechanisms and Immunotoxins (1 paper). The work is most often cited by research in Cancer Research (120 citations), Oncology (215 citations), Pulmonary and Respiratory Medicine (224 citations), Molecular Biology (330 citations) and Pathology and Forensic Medicine (50 citations). Steve Bender has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include David R. Shalinsky, Jeffrey H. Chen, Grant Wickman, Dana D. Hu‐Lowe, Patrick M. O’Connor, Michele McTigue, David A. Rewolinski, Xinglin Wu, Robert S. Kania and Maren L. Grazzini. Their work appears in journals such as Cancer Research, Clinical Cancer Research, Journal of Medicinal Chemistry, Molecular Cancer Therapeutics and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.